Attached files

file filename
EX-23.1 - EXHIBIT 23.1 - VIVEVE MEDICAL, INC.ex_220936.htm
EX-5.1 - EXHIBIT 5.1 - VIVEVE MEDICAL, INC.ex_220935.htm

 

As filed with the Securities and Exchange Commission on January 13, 2021.

Registration No. 333-       

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 


 

 

FORM S-1

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 


 

 

VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

 

 


 

 

Delaware

 

3841

 

04-3153858

(State or other jurisdiction of

 

(Primary Standard Industrial

 

(I.R.S. Employer

incorporation or organization)

 

Classification Code Number)

 

Identification Number)

 

 

345 Inverness Drive South

Building B, Suite 250

Englewood, CO 80112

Telephone: (720) 696-8100

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive office)

 

 


 

 

Scott Durbin

345 Inverness Drive South

Building B, Suite 250

Englewood, CO 80112

Telephone: (720) 696-8100

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

Mitchell S. Bloom, Esq.

Heidi Mayon, Esq.

Goodwin Procter LLP

601 Marshall Street

Redwood City, CA 94063

(650) 752-3100

 

Aron Izower, Esq.

Wendy Grasso, Esq.

Reed Smith LLP

599 Lexington Avenue

New York, NY 10022

(212) 521-5400

 


 

 

Approximate date of commencement of proposed sale to the public:

As soon as practicable after this registration statement is declared effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☒ 333-251517

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

 

Accelerated filer ☐

 

Non-accelerated filer ☒

 

Smaller reporting company ☒

 

 

 

 

 

 

Emerging growth company ☐

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities
to be Registered(1)

 

Proposed Maximum
Aggregate Offering
Price(1)(2)

 

Amount of
Registration Fee

Class A Units consisting of:

 

 

 

 

(i) Shares of common stock, par value $0.0001 per share

 

$4,600,000

 

 $501.86

(ii) Warrants to purchase common stock

 

 

Class B Units consisting of:

 

 

 

 

(i) Series C Preferred Stock, par value $0.0001 per share

 

 

(ii) Common stock issuable upon conversion of Series C Preferred Stock

 

 

(iii) Warrants to purchase common stock

 

 

Common Stock issuable upon exercise of warrants

 

$4,600,000

 

 $501.86

Total

 

 

$9,200,000

 

 

$1,003.72

(1)

Represents only the additional dollar amount of securities being registered and includes the additional dollar amount of securities that the underwriters have the option to purchase to cover over-allotments, if any. Does not include the securities that the registrant previously registered on the registration statement on Form S-1 (File No. 333-251517).

(2)

Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. Based on the public offering price per share.

 

 

THIS REGISTRATION STATEMENT SHALL BECOME EFFECTIVE UPON FILING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH RULE 462(B) UNDER THE SECURITIES ACT.

 

 

 

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

 

This Registration Statement is being filed pursuant to Rule 462(b) as promulgated under the Securities Act of 1933, as amended, and includes the registration statement facing page, this page, the signature page, an exhibit index and the required opinion and consents solely to register up to an aggregate of $9,200,000 in (i) additional Class A Units, with each Class A Unit consisting of one share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and one warrant to purchase one share of Common Stock, (ii) additional Class B Units, with each Class B Unit consisting of one share of the Company’s Series C preferred stock, par value $0.0001 per share (the “Series C Preferred Stock”), and one warrant to purchase one share of Common Stock, (iii) shares of Common Stock issuable upon conversion of the additional shares of Series C Preferred Stock and (iv) shares of Common Stock issuable upon exercise of the warrants included in the additional Class A Units and Class B Units. The contents of the Registration Statement on Form S-1 (File No. 333-251517), as amended, including the exhibits and power of attorney thereto, which was declared effective by the Securities and Exchange Commission on January 13, 2021, are incorporated by reference in this Registration Statement.

 

 EXHIBIT INDEX

 

Exhibit No.

 

Description

5.1

 

Opinion of Goodwin Procter LLP.

23.1

 

Consent of BPM LLP, independent registered public accounting firm.

23.2

 

Consent of Goodwin Procter LLP (See Exhibit 5.1 hereto).

24.1

 

Power of Attorney (included on the signature page to the Registration Statement on Form S-1 (File No. 333-251517) filed by the Registrant on December 18, 2020).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Englewood, State of Colorado, on January 13, 2021.

 

 

VIVEVE MEDICAL, INC.

 

 

 

 

 

 

 

 

 

By:

/s/ Scott Durbin

 

 

Name:

Scott Durbin

 

 

Title:

Chief Executive Officer

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/S/ Scott Durbin

 

Chief Executive Officer, President and Director

 

January 13, 2021

Scott Durbin

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/S/ Jim Robbins

 

Vice President of Finance and Administration

 

January 13, 2021

Jim Robbins

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

*

 

Chairman and Director

 

January 13, 2021

Steven Basta

 

 

 

 

 

 

 

 

 

*

 

Director 

 

January 13, 2021

Arlene Morris

 

 

 

 

 

 

 

 

 

*

 

Director

 

January 13, 2021

Debora Jorn

 

 

 

 

 

 

 

 

 

*

 

Director

 

January 13, 2021

Sharon Collins Presnell

 

 

 

 

 

 

 

 

 

 

*By:

/s/ Scott Durbin

 

 

Scott Durbin, Attorney-in-Fact